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A-2 plaque virus (A2 virus) was originally isolated from the icteric-phase sera of US servicemen with viral hepatitis in the
1960s, but apart from a preliminary characterization little is known about the agent. We have now successfully cloned and
sequenced the complete viral genome. A2 viral RNA consists of 7312 nucleotides, excluding the 62 nucleotide poly(A) tract
at the 39 end, with one large open reading frame. Although clearly a member of the Picornaviridae, there is low homology to
the available sequences, suggesting it is only loosely related to the classic rhino/enterovirus genus. In addition, there was
no reactivity with group specific monoclonal antibody blends against polioviruses, enteroviruses 70 and 71, coxsackievirus
B, and echoviruses. Two tamarins were inoculated with A2 virus to study viral pathogenesis. Both animals that received A2
virus became transiently viremic 1 week after the infection, as determined by RT–PCR, and they developed an antibody
response to A2 virus. However, no physical signs or biochemical abnormalities, including elevated liver transaminases, were
observed. In addition, no liver samples from patients with fulminant hepatitis (n 5 7) or controls (n 5 7) were positive for A2
viral RNA nor was anti-A2 neutralizing antibody detected in sera from hepatitis patients (n 5 14), healthy laboratory donors
(n 5 14), or US blood donors (n 5 33); however, most sera contained antibodies reactive with A2 virus proteins. These results
suggest that A2 virus is a new member of the Picornaviridae but that its pathogenicity in nonhuman primates and association
with human disease still need to be determined. © 2000 Academic Press
Key Words: Picornavirus; A2 virus; enterovirus; hepatitis.
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tINTRODUCTION
Despite the identification of hepatitis C and hepatitis E
in recent years, the etiology of ;30% of seronegative
hepatitis in America remains unknown (Rochling et al.,
1997). In addition, the causative agent for fulminant hep-
atitis of childhood and hepatitis-associated aplastic ane-
mia (Brown et al., 1997a) also remains elusive and does
not appear to be associated with the putative hepatitis
viruses HGV/GBV-C (Brown et al., 1997a,b) or TTV (Ma-
sumoto et al., 1999). In 1963, prior to the identification of
epatitis A, a virus was isolated from the icteric-phase
era of US soldiers in Korea with documented viral hep-
titis (Conrad, 1965) and was named A-2 plaque virus (A2
irus) (Shaw et al., 1973). This virus did not react with any
f the enterovirus sera panels but appeared to be sen-
itive to RNase, suggesting that it could be an enterovi-
us (Shaw et al., 1973). However, subsequent electron
icroscopy studies suggested that the virions ranged in
ize from 24 to 42 nm in diameter, and it was also
eported that immunization with A2 virus could induce
ntibody to both hepatitis B in experimental animals
Shaw et al., 1973) and hepatitis A virus (HAV) (Shaw,
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168978). As part of our studies to identify novel hepatitis
gents and to clarify the taxonomy of A2, the possible
athogenicity, and its potential association with human
iseases including hepatitis, we have characterized the
irus by analysis of its antigenic relations to other en-
eroviruses, the cloning and sequencing of the A2 virus
enome, inoculation of animals with virus, and detection
f A2 virus genome and antibody in human samples.
RESULTS
eactivity with picornaviral monoclonal antibodies
nd PCR for hepatitis A, hepatitis B and enteroviruses
Vero cells were infected with A2 virus (obtained from
TCC) and tested for the presence of known enterovi-
uses or hepatitis agents by immunofluorescence or
CR. There was no reactivity of A2 virus with any of the
roup specific antibody mixes or with the broadly reac-
ive enterovirus monoclonal antibody by immunofluores-
ence (Table 1). In addition, RT–PCR and PCR assays for
epatitis A and hepatitis B were negative, indicating that
2 did not contain either of these viral sequences. A
roduct of the correct size was obtained when one set of
rimers designed to amplify a region from the conserved
9 nontranslated region (NTR) of enteroviruses was used
o perform RT–PCR, although no product was obtained
hen the other primer pair was used. The positive PCR
roduct was cloned and sequenced: there was no match
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169SEQUENCING OF THE A-2 PLAQUE VIRUSof the sequence in GenBank, suggesting that A2 con-
tained a novel viral genome. To obtain more sequence, a
phage library was constructed from A2-infected Vero
cells, and by primer walking, using primers designed
from the unique sequence and from the phage se-
quence, the whole A2 sequence was systematically am-
plified, cloned and sequenced.
Sequence analysis
The A2 virus genome was found to be 7312 bases in
length excluding the 62 nucleotide 39 (poly)A tail (viral
sequence AF201894 in GenBank). Computer-assisted
analysis of the nucleotide sequence of A2 virus indicated
that the genomic RNA contained one large open reading
frame (ORF nt 654-7247), encoding a putative polyprotein
of 2197 amino acids. The organization of the A2 viral
genome resembled that of a typical picornavirus with
similar sized 59 and 39 noncoding regions and terminal
T
Properties of the Monoclonal Antibodies to Enteroviruses a
Monoclonal antibodies Presumptiv
Enterovirus blend Enterovirus 70 and/or 71
oliovirus blend Poliovirus group 1, 2, or 3
oxsackievirus B blend Coxsackievirus group B1, B2, B3, B
chovirus blend Echoviruses 4, 6, 9, 11, 30, and 34;
and some isolates of coxsackiev
nti-enterovirus monoclonal
antibody clone 5-D8/1
Most of the enterovirus strains of th
T
Genomic Features and P
Gene
Nucleotide sequence
Start End Length
59NTR 1 653 653
Polyprotein 654 7244 6591
P1 654 3266 2613
P2 3267 4991 1725
P3 4992 7244 2253
VP0 654 1610 957
P4 654 860 207
P2 861 1610 750
P3 1611 2327 717
P1 2328 3266 939
2A 3267 3707 441
2B 3708 4004 297
2C 4005 4991 987
A 4992 5252 261
B 5253 5318 66
C 5319 5867 549
D 5868 7244 1377
9NTR 7245 7312a 68aa The poly-A tail was not included.(poly)A tract (Table 2). The base composition of A2 virus
genome was composed of 29.3% adenine, 23.6% gua-
nine, 19.7% cytosine, and 27.4% uracil. The high A1U
content (57%) was similar to those of enteroviruses (PV-1,
A1U 5 54%) and rhinoviruses (HRV-1B, A1U 5 63%)
The complete polyprotein of A2 virus had between 13
and 47.9% identity with representatives of the six other
genera (Pringle, 1999) and the two newly described gen-
era (Yamashita et al., 1998; Doherty et al., 1999) in the
picornavirus family, with polioviruses and rhinoviruses
having relatively higher homology (47.9 and 39.7% re-
spectively, Table 3). Similarly, the A2 virus 59 NTR
showed highest similarity to poliovirus and enterovirus:
there was no polypyrimidine tract characteristic of the
cardio-, aphtho-, hepato-, or parechoviruses (Rueckert,
1996). The A2 virus 39 NTR was more distinctive. Its
length (66 nucleotides) was closest to HAV (63 nt) rather
than PV (71 nt) or HRV (42 nt HRV-2), and the closest
ir Reactions with A2 Virus in Immunofluorescence Assays
ification or reactions A2 virus reactions
Negative
Negative
r B6 Negative
ross reactivity with poliovirus 1, 2, and 3 Negative
virus, coxsackievirus, and poliovirus groups Negative
ed Proteins of A2 Virus
Amino acid sequence
MW (kDa)Start End Length
— — — —
1 2197 2197 224.9
1 871 871 76.2
872 1446 575 64.7
1447 2197 751 84.0
1 319 319 15.0
1 69 69 7.6
70 319 250 27.4
320 558 239 26.4
559 871 313 34.8
872 1018 147 16.2
1019 1117 99 10.8
1118 1446 329 37.7
1447 1533 87 9.6
1534 1555 22 2.4
1556 1738 183 19.8
1739 2197 459 52.2
— — — —ABLE 1
nd The
e ident
4, B5, o
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e echoABLE 2
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3
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170 LIU ET AL.sequence similarity was to the rhino- and hepatoviruses
(HRV-1B, 37%; HAV, 33%, Table 3).
Due to the closest similarity to the enteroviruses and
rhinoviruses, further comparisons of A2 virus with the
members in these genera were performed. The A2 virus
polyprotein had 52–57% identity with these viruses, but
with no virus did the sequence similarity exceed 70%
(data not shown).
By sequence alignment with other known picornavi-
ruses, it was hypothesized that the A2 polyprotein is
cleaved to produce 11 end products, forming its struc-
tural and nonstructural proteins (Table 2). The predicted
cleavage sites of the A2 virus polyprotein were identical
to those of the enteroviruses except VP4-VP2 (which is
N-S in PV-1). In addition, the sequence for the predicted
2A proteinase had the classical catalytic triad, His, Asp,
Cys (His18, Asp36, Cys107), seen in the entero- and rhino-
viruses (Ryan and Flint, 1997). The putative 2C, 3C, and
3D proteins all contained the characteristic signature
motifs found in all known picornaviruses: ATP/GTP bind-
ing site (2C ATP/GTP binding site, aa 1246–1263; 2A viral
helicase, aa1242–1253; 3C Cys/His proteinase motifs—
His40 Glu71 Cys147, aa 1595–1702; 3D GDD polymerase
motif, 2062–2064). Phylogenetic analyses using the A2
virus 3C proteinase proteins, which have a high degree
of sequence similarity across the Picoranviridae (Ryan
and Flint, 1997), showed similar results with the polypro-
tein sequence comparison with closest similarity to en-
teroviruses/rhinoviruses (Fig. 1). However, the virus was
T
Comparisons of Nucleic Acid (59NTR and 39NTR) and Amino Acid
Region
Entero-
polio-1
Rhino-
HRV-1B
Cardio-
EMCV
Parecho-
ECHO-22
59NTR 40.9 48.2 21.4 22.8
Polyprotein 47.9 39.7 20.1 15.6
P1 41.9 41.9 20.8 13.1
P2 52.9 38.3 19.7 18.1
P3 59.0 49.3 21.3 18.9
VP0 55.8 52.4 26.3 17.3
VP3 43.7 40.8 27.3 10.0
VP1 33.4 34.5 13.7 10.8
2A 49.0 33.8 9.5 12.2
2B 43.3 40.0 14.1 16.2
2C 57.8 40.1 26.7 23.4
3A 44.8 36.4 12.6 12.6
3B (Vpg) 54.5 38.1 35.0 26.3 2
C 48.9 47.0 13.7 16.4
D 66.0 53.6 27.5 22.0
9NTR 23.5 36.8 25.0 26.5
2 random 9.8 9.3 10.4 9.6
2 random 9.8 8.9 9.9 9.6
a Percent identity calculated by Clustal method with a gap penalty o
aseline calculated using a random generated sequence based on A
b The three Vpg’s were separately compared with those of other virusignificantly different from any known member, although
it was slightly closer to the human rhinovirus group (Fig. 2).Tamarin inoculation studies
Four tamarin monkeys were used for inoculation stud-
ies; two animals were inoculated with virus and the other
two animals were used as controls. Post inoculation
serum and fecal samples were collected, RNA was ex-
tracted and A2 RT–PCR performed. Both animals inocu-
lated with A2 virus had detectable viremia 1 or 2 weeks
after inoculation (Fig. 3). However, virus was not detected
in any of the fecal samples, despite identification of virus
in A2-spiked fecal material tested in parallel.
A2 seroconversion in the animals was monitored in
the tamarins by detection of anti-A2 IgG antibodies using
A2-infected Vero cells and indirect immunofluorescence.
Weakly reactive antibodies were detectable in one ani-
mal, M260, prior to inoculation, but serum samples be-
came strongly positive at 4 weeks p.i. In the second
animal, 3939, seroconversion occurred by week 2 (Fig.
3). Serum samples taken 9 months p.i., one from tamarin
3939 and the other from one of the controls animals,
were tested for A2 virus neutralizing antibody but neither
was positive.
No biochemical and clinical abnormalities, includ-
ing hepatitis, were observed in either of the inoculated
tamarins and the controls. Liver samples were not
examined.
Detection of A2 in human samples
nces of A2 Virus with Representatives of Other Picornavirusesa
o-
-OK
Hepato-
HAV
Aichi
virus
Porcine
PEV-1
Random
A2
Random
A2
3 21.0 23.1 26.3 19.9 18.5
0 13.0 15.9 15.2 9.6 9.9
5 12.8 11.5 17.0 9.8 9.9
2 16.0 15.1 19.1 9.6 10.3
4 16.1 20.6 20.8 10.8 10.4
8 17.3 16.6 23.8 9.7 10.7
7 12.6 24.6 21.3 9.6 10.9
8 12.3 12.9 14.1 10.9 9.9
9 14.3 12.6 28.6 10.9 9.5
1 16.2 14.1 13.1 14.1 11.1
7 19.5 18.8 23.7 9.7 10.9
5 14.9 14.9 10.3 10.3 12.6
/22.7b 22.7 18.2 13.6 9.1 13.6
1 14.2 14.2 16.4 11.5 11.5
0 19.4 26.4 30.0 10.9 9.8
0 33.3 26.5 23.5 20.6 19.1
6 9.9 9.7 9.7
9 9.7 10.0 10.7
p length penalty of 10, and PAM250 as the comparison scoring table.
otide or amino acid sequence, respectively.ABLE 3
Seque
Aphth
FMDV
21.
15.
15.
17.
20.
10.
12.
10.
12.
14.
21.
12.
2.7/27.3
13.
27.
25.
9.
9.
f 10, gaRNA was extracted from control livers and patients
with fulminant hepatitis and A2 RT–PCR performed. A2
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171SEQUENCING OF THE A-2 PLAQUE VIRUSviral RNA was not detected from any of the liver samples.
Serum samples were not available for these patients
Western blot analysis was performed in 91 human
serum samples. Thirteen/14 laboratory staff, 14/14 hep-
atitis-associated aplastic anemia patients (Fig. 4), 32/33
American blood donors, and 29/30 Vietnamese blood
donors had strong reaction to a band with a molecular
weight of ;38 kDa, and 2/14 laboratory staff, 6/14 pa-
tients with hepatitis-associated aplastic anemia (Fig.4),
10/33 American blood donors, and 12/30 Vietnamese
blood donors had reactivity to a protein with a molecular
weight of ;26 kDa
The identity of the reactive proteins was determined by
expressing the A2 viral proteins VP1, VP2, VP3, and 2C
(according to the predicted cleavages of A2 virus
polyprotein) in Escherichia coli. The 38-kDa protein cor-
responded to the VP1 protein of A2 virus and the 26-kDa
protein to the VP3 capsid (data not shown).
None of the sera from the laboratory donors and the
FIG. 1. Phylogenetic tree of A2 virus (GenBank, AF201894) with other
picornaviruses based on amino acid differences of 3C proteinase
proteins generated by Clustal method. The alignments were calculated
with Clustal W (using the default settings) and the tree generated from
the PHYLIP alignment using TreeView (Page, 1996). Sequences used
are: Aichi virus, AB010145; echovirus 22 (ECHO-22), S45208 L00675;
encephalomyocarditis virus (EMCV), X74312; foot and mouth disease
virus (FMDV-OK), X00871; hepatitis A virus (HAV), M14707; human
poliovirus type 1 (Mahoney strain, Polio-1), V01148; human rhinovirus
1B (HRV-1B), D00239; porcine enterovirus 1 serotype 1 (PEV-1),
AJ011380.patients with hepatitis-associated aplastic anemia had
detectable neutralizing antibody (with sera diluted seri-ally from 1:4). American blood donors (n 5 33) also were
uniformly negative.
DISCUSSION
Although A2 virus was first isolated 30 years ago
(Shaw and Banks, 1966) and initial studies indicated that
this virus had many characteristics similar to those of
Picornaviridae, little was known about this virus in its
molecular characteristics and its precise taxonomical
position in the picornavirus family. In the original report,
no reactivity was observed using anti-enteroviral sera in
plaque forming units (PFU) inhibition tests (Shaw et al.,
1973), and we likewise could detect no reactivity with a
variety of monoclonal antibody mixes or with a monoclo-
nal against a conserved enteroviral epitope (Table 1),
suggesting that A2 is antigenically distinct from known
enteroviruses. The identification of the full length se-
quence of A2 confirmed that this was a novel agent.
In the present study, we successfully sequenced the
full sequence of A2 virus, which enabled us to compare
A2 virus with other viruses at the nucleic acid and protein
levels. We were also able to investigate this virus by
using more specific detection methods, including PCR.
The members of the picornavirus family are classified
into six different genera, aphtho-, cardio-, entero-, rhino-
hepato-, and parechoviruses (Mayo and Pringle, 1998;
Pringle, 1999). More recently, two new genera of the
viruses in picornavirus family have been proposed (Ya-
mashita et al., 1998; Doherty et al., 1999). The genome
length, its organization, the composition of the nucleic
acid sequence, the sizes of the predicted polyprotein,
and the location of its cleavage sites all suggest that A2
virus resembles the viruses in the Picornaviridae.
The comparisons of the 59 NTR nucleic acid se-
uences and the predicted protein sequences of A2 virus
ith representatives in each of the six genera and the
wo newly claimed genera in the picornavirus family
howed that A2 virus was not identical to any of them,
lthough it was loosely related to polioviruses and hu-
an rhinoviruses. Phylogenetic analysis of A2 virus with
ther picornaviruses showed similar results as did the
equence comparisons. However, A2 virus was also not
losely related to any of the known/sequenced members
f either the enteroviruses or rhinoviruses, suggesting
hat it is a novel agent.
The increased similarity of the 39 NTR with HAV was
urprising, as there was little similarity in the rest of the
enome. The 39 NTR of picornaviral RNA may play a role
n the virus RNA replication, as it is known that it is
equired for efficient genome (Rohll et al., 1995), and the
difference between enteroviruses and human rhinovi-
ruses in 39 NTR is thought to be related to their distinct
cell tropism and temperature optima (Mirmomeni et al.,
1997; Todd et al., 1995). It is unclear whether the 39 NTR
ses ba
y, 10; g
172 LIU ET AL.also conveys to A2 hepatotropic properties similar to
those of HAV.
In previous studies, patas monkeys inoculated with A2
virus remained asymptomatic, although no studies were
done to determine the presence of viremia (Shaw et al.,
1973). In our study, we chose to use tamarins, as they
have been useful non-human primate models for hepa-
titis A studies (Poleshchuk et al., 1990, 1992). Although
we were successful in inducing viremia in tamarins in-
oculated with A2, there was no evidence of clinical dis-
ease, including hepatitis. As for other hepatitis viruses,
chimpanzees may be a better animal model (Garson et
al., 1997; Bukh et al., 1998). However, both tamarins also
demonstrated development of A2 antibodies following
inoculation suggesting a specific response to A2 viral
proteins. In one inoculated animal, the antibody was
FIG. 2. Phylogenetic tree of A2 virus with enteroviruses and rhinoviru
in Ryan and Flint (1997) and generated by Clustal method (gap penaltweakly detectable before the virus inoculation, perhaps
indicating previous infection with either A2 or a relatedvirus—although clearly this antibody response did not
prevent reinfection.
Perhaps surprisingly, we were unable to detect fecal
excretion of A2 virus in either monkey, despite being able
to detect virus in A2-spiked fecal material, making un-
likely the presence of PCR inhibitors in the sample (Uwa-
toko et al., 1996; Ali et al., 1998). Lack of detection of A2
RNA in stool may indicate that fecal excretion occurs
only at low levels or there is intermittent excretion or that
the virus does not replicate in the digestive tract like true
enteroviruses. [A2 virus was originally isolated from sera
(Conrad, 1965), not fecal material.] It is also noteworthy
that the sequence homology indicated that A2 virus was
loosely related to rhinoviruses, and perhaps A2 virus like
rhinovirus is unable to replicate in the intestinal tract or to
be excreted in fecal specimens; also characteristic of rhi-
sed on amino acid differences of 3C proteinase proteins as described
ap length penalty, 10; weighted table, PAM250).noviruses is the rarity of detectable viremia and short-lived
or absent neutralizing antibody production (Couch, 1996).
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173SEQUENCING OF THE A-2 PLAQUE VIRUSIn the limited number of human livers examined, we
did not detect A2 viral RNA in any of the samples,
suggesting that this virus is not a major cause of fulmi-
nant hepatitis in the United States. Similarly, we did not
detect the more specific neutralizing antibodies in any of
the samples that we looked at, although antibodies that
reacted with A2 VP1(38-kDa protein) and VP3 (26-kDa
protein) were present in laboratory donors, hepatitis pa-
tients, and blood donors. Cross reactivity to capsid pro-
teins, especially VP1 and VP3 has been shown with other
enteroviruses (Mertens et al., 1983; Pulli et al., 1998) and
resumably indicates exposure to other members of the
icornaviridae.
A2 virus was originally isolated from American ser-
icemen in Korea. Therefore, a possible endemic geo-
raphical distribution of the virus may contribute to the
linical results. However, we found similar results when
0 serum samples from Vietnamese blood donors were
ssayed for A2 virus IgG antibody (29/30 and 12/30
amples had A2 virus VP1 and VP3 reactive antibodies,
espectively, data not shown), although we have not
xamined samples from Korea, where this virus was
riginally isolated. However, as noted above, enterovi-
uses show enormous cross reactivity, and serological
ssays on single samples for antibody prevalence are
ifficult, if not impossible, to interpret.
Currently, our studies of animals and of human sam-
FIG. 3. A2 virus genome and IgG antibody detection results in tamarin
during the first 5 weeks of observation. (A) Nested PCR results detecte
and probed by using 32P-end-labeled A2-P2 probe, the correct products
ndirect immunofluorescence. WK, weeks p.i.; N, negative control; P, p
FIG. 4. A2 virus IgG antibody in lab donors and patients with hep
olecular weights are shown on the left and the ;38 (top) and ;26 kDa (bott
anemia.ples do not suggest either pathogenicity of A2 virus in
tamarins or the association of A2 virus with human hep-
atitis. However, we believe further investigation of this
novel virus is warranted, especially to determine a sus-
ceptible animal (Garson et al., 1997; Bukh et al., 1998)
nd also because of the wide spectrum of diseases
ssociated with other picornaviral infections, many of
hich may be asymptomatic in the majority of patients
Muir et al., 1998).
MATERIALS AND METHODS
Virus, virus growth, and purification
A-2 plaque virus was obtained from the American Type
Culture Collection (ATCC, Manassas, VA), and grown in
Vero cells (ATCC) in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2% fetal calf serum (FCS)
and antibiotics. Cells were harvested when the mono-
layer was completely destroyed (generally within 3 days),
and cell debris was removed by low-speed centrifuga-
tion (4000 g for 10 mins) after three freeze–thaw cycles.
Virus was purified from the supernatant by treatment
with an equal volume of chloroform for 15 min and cen-
trifugation through 30% sucrose cushion (Beckman, SW
55 rotor, 40,000 rpm, 4°C, 5 h). The A2 virus pellet was
suspended in phosphate buffer saline (PBS) and stored
at 280°C until use.
(one of the controls) and 3939 (one of the A2 virus inoculated animals)
ing outside primers A2–1 and A2–2 and inside primers A2–3 and A2–4
have a molecular size of 190 bp. (B) A2 virus IgG results detected by
control.
ssociated aplastic anemia detected by immunoblotting. The proteins M299
d by usatitis-a
om) bands are indicated by arrows. HAA, hepatitis-associated aplastic
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174 LIU ET AL.Reactivity with picornaviral monoclonal antibodies
Vero cell monolayers were inoculated with A2 virus (or
mock infected) and grown for 2 days or until 30–50% of
cells showed evidence of a viral cytopathic effect (CPE).
The cells were rinsed with PBS and scraped into solu-
tion, and 15 mL was placed on individual rings of a
luorescent antibody slide (Bellco Glass, Inc., Vineland,
J). After being allowed to air dry completely, the slides
ere fixed in acetone (4°C) for 30 min. Monoclonal
ntibody mixes (Table 1) were purchased from Chemicon
nternational (Temecula, CA) and used as supplied.
onoclonal antibody 5-D8/1 (DAKO, Glostrup, Denmark)
as diluted 1:20 in PBS. Antibodies were incubated with
lides at 37°C for 30 min and then washed. Anti-mouse
gG-FITC (1:50 diluted) (BioSource International, Cama-
illo, CA) was used as a secondary antibody in the same
rocedure.
CR for hepatitis A, hepatitis B, and enteroviruses
Viral nucleic acid was extracted from infected tissue
ulture supernatant using the QIAamp Blood Kit (Qiagen
nc., Valencia, CA) with the addition of yeast tRNA to act
s carrier. Viral RNA was converted to cDNA using ran-
om hexamers (GeneAmp RNA PCR Core kit; Perkin–
lmer, Foster City, CA). Amplification was performed us-
ng primers from the 59 nontranslated region of hepatitis
(nts 65–84 or 241–260 and nts 706–687), the core
egion of hepatitis B (primers HB-S, 59-GGATTGGGGAC-
CTGCGC-39 and HB-AS, 59-CCCAATACCACATCATCC-
9), the conserved 59 nontranslated region of enterovi-
uses [Pr2 and Pr5 (Clewley, 1995)], and the conserved
nteroviral 3D RNA polymerase encoding region (Pulli et
l., 1995). PCR was carried out in all cases using ExTaq
olymerase (Panvera Corp., Madison, WI) and 30 cycles
f amplification (94°C, 60s; 30 cycles of 92°C, 40s, 60°C
or 90 s, and 75°C for 60s, followed by a final extension
t 75°C for 5 min). The PCR products were analyzed by
garose gel electrophoresis.
onstruction of cDNA phage library
A2 virions were precipitated from infected tissue cul-
ure supernatant (50 ml) by PEG precipitation (Minor,
985), resuspended in 1 ml of PBS with 1% bovine serum
lbumin, and RNA extracted using RNEasy kit (Qiagen). A
irectional lambda phage cDNA library was constructed
Choice kit, Life Technologies) and packaged according
o standard protocols. The library (5 3 105 pfu) was
amplified once before use.
Nucleotide sequencing
The sequence at the 59 nontranslated region (NTR) of
the virus was obtained by sequencing PCR products
amplified by the enterovirus 59 NTR primers and TA
cloned into pCR 2.1 vector (Invitrogen Corp., Carlsbad,CA). The subsequent sequences were amplified by prim-
ers walking using one primer designed from the previ-
ously obtained sequence and the other from the phage
sequence (59-GCATGCACGCGTACGTAAGC-39). The am-
plified products were TA cloned into pCR 2.1 vector and
sequenced by cycle sequencing (Dye Terminator Cycle
Sequencing, Perkin–Elmer). At least three clones were
sequenced for each amplified product from two direc-
tions. Sequence comparisons between A2 virus and
other picornaviruses were performed using Lasergene
software (DNAStar Inc., Madison, WI), and ClustalW
(Thompson et al., 1994) at the European Bioinformatics
Institute (http://w2.ebi.ac.uk/clustalw). The Accession
numbers of picornavirus sequences used in the analysis
are as follows: Aichi virus AB010145 (Yamashita et al.,
1998); echovirus 22 (ECHO-22) S45208 L00675 (Hyypia¨ et
al., 1992); encephalomyocarditis virus (EMCV) X74312
(Zimmermann et al., 1994; Nelsen-Salz et al., 1996); foot
and mouth disease virus (FMDV-OK) X00871 (Forss et al.,
1984); hepatitis A virus (HAV) M14707 (Cohen et al.,
1987); human poliovirus type 1 (Mahoney strain, Polio-1)
V01148 (Dorner et al., 1982; Emini et al., 1982; Kitamura
and Wimmer, 1980; Kitamura et al., 1980, 1981; Racaniello
and Baltimore, 1981); human rhinovirus 1B (HRV-1B)
D00239 (Hughes et al., 1988); porcine enterovirus 1 se-
rotype 1 (PEV-1) AJ011380 (Doherty et al., 1999).
Animal studies
Tamarin (S. mystax) studies were preformed under a
protocol approved by the NHLBI Animal Care and Use
Committee. Two tamarins (M260 and 3939) were inocu-
lated intravenously with 1 ml supernatant of Vero cell
culture infected with A2 virus (;4 3 105 TCID50). Two
nimals were inoculated with PBS to act as controls.
oth pairs of animals were housed separately to prevent
ross-infection, and the animals were observed for evi-
ence of clinical disease; blood and fecal samples were
ollected weekly.
Total RNA was extracted from 100 ml of tamarin blood
RNA STAT-60; Tel-test, Inc., Friendswood, TX) and resus-
ended in 25 ml RNase-free water. Fecal material was
suspended in PBS, vortexed and centrifuged at 15,000 g
and 4°C for 15 min. Fecal supernatant (60 ml) was mixed
with 600 ml Catrimox-14 (Ali et al., 1998) (Qiagen) and
ncubated at room temperature for 15 min prior to extrac-
ion of viral RNA (Qiamp RNA blood kit, Qiagen). The RNA
as eluted into 35 ml water containing 20 U RNase
inhibitor (RNase OUT, Life Technologies). Confirmation of
the extraction method was performed by testing A2-
spiked fecal samples in parallel.
Human samples
Liver samples from patients undergoing liver trans-
plantation for fulminant hepatitis (n 5 7) or biliary atresia
(as controls, n 5 7) were provided by LTPADS, Minne-
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175SEQUENCING OF THE A-2 PLAQUE VIRUSsota. RNA was extracted from tissues using the QIAamp
Tissue Kit (Qiagen). In addition sera were obtained from
patients admitted to NIH and diagnosed as hepatitis-
associated aplastic anemia (n 5 14), volunteer labora-
tory staff (n 5 14), anonymized NIH Clinical Center blood
donors (n 5 33), and Vietnamese blood donors (n 5 30)
on IRB approved protocols.
A2 RT–PCR assay
RNA was converted to cDNA by reverse transcription
using random hexamers, as described above. Amplifica-
tion was performed using primers in two different re-
gions of the viral genome: one-step amplification with
primers in the 59 noncoding region (primers A2-S, nt
112–131; A2-A, nt 464–445); or nested PCR with primers
in the polymerase region (outside primers A2–1, nt 6570–
6589 and A2–2, nt 6976–6957; inside primers, A2–3, nt
6715- 6734 and A2–4, nt 6904–6885). PCR conditions
were as above, with 5 ml of the first-round PCR products
used as template in the second round of amplification.
Products were analyzed by Southern blotting using two
32P-end-labeled probes, A2-P1 (nt 263–292) and A2-P2 (nt
834–6863), respectively.
nti-A2 immunofluorescence and Western blot
For immunofluorescence studies spot slides were pre-
ared as above and incubated with serum samples di-
uted 1:50 in PBS plus 10% bovine serum albumin (BSA)
or 30 min at 37°C. After washing the slides were incu-
ated with goat anti-human IgG-FITC (1:50 dilution; Bio-
ource International) for 30 mins at 37°C, washed, and
xamined by UV microscopy.
For Western blot, purified A2 viral proteins were sep-
rated by SDS–PAGE electrophoresis and then trans-
erred to nitrocellulose membranes. Nonspecific binding
as blocked by incubation with blocking buffer (PBS,
.05% Tween 20 plus 5% nonfat dried milk) for 1 h (RT),
he membrane cut into strips, and incubated with human
erum samples (diluted 1:200 in blocking buffer) for 1 h
RT). After washing three times with PBST (PBS, 0.05%
ween 20), the strips were incubated with HRP-conju-
ated goat anti-human IgG (1:10000 in blocking buffer;
ioSource International) for 1 h (RT) and rewashed. Im-
unoreactivity was detected by enhanced chemilumi-
escence (ECL, Pierce, Rockford, IL).
eutralization test
The test for A2 virus neutralization was based on
nhibition of cytopathic effect (CPE) as previously de-
cribed (Hsiung, 1994). Briefly, 96-well culture plates
ere seeded with Vero cells and incubated until a 50–
0% monolayer was formed. Twofold serial dilutions of
he sera were preincubated with A2 virus (100 TCID50) for
h (RT) and then added to cells; for each serum dilution,our parallel wells were inoculated, and the cultures
ere checked for CPE daily for 7 days.
xpression of A2 proteins
A2 virus genes encoding viral proteins VP1, VP2, VP3,
nd 2C according to the predicted cleavages were sep-
rately cloned into pTrcHis2-TOPO TA vectors (Invitrogen
orporation) and the corresponding fusion proteins were
xpressed by the induction of 1 mM IPTG.
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